Shopping Cart
- Remove All
Your shopping cart is currently empty
Lipocalin-2/LCN2 Protein, Human, Recombinant (His) V2 is expressed in HEK293 Cells. The accession number is P80188-1.

| Pack Size | Price | Availability | Quantity |
|---|
| Biological Activity | Immobilized Human NGAL, His Tag at 0.2 μg/ml (100 μl/Well) on the plate. Dose response curve for Anti-NGAL Antibody, hFc Tag with the EC50 of 7.8 ng/ml determined by ELISA. |
| Description | Lipocalin-2/LCN2 Protein, Human, Recombinant (His) V2 is expressed in HEK293 Cells. The accession number is P80188-1. |
| Species | Human |
| Expression System | HEK293 Cells |
| Tag | C-His |
| Accession Number | P80188-1 |
| Synonyms | p25,NGAL,MSFI,Lipocalin-2,lipocalin 2,24p3 |
| Construction | Gln21-Gly198 |
| Protein Purity | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| Molecular Weight | 21.64 kDa (Predicted); 25-30 kDa (Due to glycosylation) |
| Endotoxin | < 1.0 EU/μg of the protein as determined by the LAL method. |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Stability & Storage | Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| Shipping | In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice. |
| Research Background | Acute kidney injury (AKI) is one of the most common complications of various serious conditions, and early diagnosis is therefore critical for the treatment of AKI. Recent evidence demonstrates that neutrophil gelatinase- associated lipocalin (NGAL) is closely associated with AKI. Several experimental and clinical studies have shown that the expression of urine and serum NGAL increases significantly in AKI. NGAL shows potential to be a new effective early biochemical marker of AKI. Further studies are needed to confirm the significant advantages of NGAL in the diagnosis of early AKI and its value in clinical applications. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.